

	CHANCE (2013)	POINT (2018)	THALES (2020)	INSPIRES (2023)
Population	China	10 countries – North America, Europe, Australia/NZ	28 countries	China
Minor stroke definition	NIHSS ≤ 3	NIHSS ≤ 3	NIHSS ≤ 3	NIHSS ≤ 5
High-risk TIA definition	ABCD ² ≥ 4	ABCD ² ≥ 4	ABCD ² ≥ 4	ABCD ² ≥ 4
Key inclusion criteria			Attributable $\geq 50\%$ ipsilateral atherosclerotic stenosis	Attributable $\geq 50\%$ atherosclerotic stenosis (intracranial/extracranial) OR Multiple acute infarcts attributable for large-artery atherosclerosis (including ipsilateral non-stenotic unstable plaque)
N	5170	4881	11,016	6100
Time: onset → randomization	$\leq 24\text{h}$	$\leq 12\text{h}$	$\leq 24\text{h}$	$\leq 72\text{h}$
Intervention	Clopidogrel + ASA	Clopidogrel + ASA	Ticagrelor + ASA	Clopidogrel + ASA
Control	ASA			
DAPT treatment duration	21 days	90 days	30 days	21 days
Follow-up	90 days	90 days	30 days	90 days
Primary efficacy outcome	Stroke	Ischemic stroke, MI, ischemic vascular death	Stroke or death	Stroke
	HR 0.68 (0.57 – 0.81), 8.2% vs 11.7%	HR 0.75 (0.59 – 0.95), 5.0% vs 6.5%	HR 0.83 (0.71 – 0.96), 5.5% vs 6.6%	HR 0.79 (0.66 – 0.94), 7.3% vs 9.2%
Key secondary efficacy outcomes	Stroke, MI, vascular death	Stroke	Ischemic stroke	Stroke, MI, vascular death
	HR 0.69, 8.4% vs 11.9%	HR 0.74, 4.8% vs 6.4%	HR 0.79, 5.0% vs 6.3%	HR 0.80, 7.5% vs 9.3%
Primary safety outcome	Moderate-severe bleeding	Major hemorrhage	Severe bleeding	Moderate-severe bleeding
	HR 0.84 (0.30 – 2.31), 0.4% vs 0.3%	HR 2.32 (1.10 – 4.87), 0.9% vs 0.4%	HR 3.99 (1.74 – 9.14), 0.5% vs 0.1%	HR 2.08 (1.07 – 4.04), 0.9% vs 0.4%